Study guide

6.2 Hematologic Small-Molecule Kinase Inhibitors

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

6.2 Hematologic Small-Molecule Kinase Inhibitors

Key Takeaways Explain This Topic AI

BCR-ABL1 TKIs represent the benchmark of precision oncology in CML and Ph+ ALL; agent selection among imatinib (1st gen), dasatinib/nilotinib/bosutinib (2nd gen), ponatinib (3rd gen), and asciminib (allosteric STAMP inhibitor) depends on baseline cardiovascular risk, mutation profile (especially T315I), and ELN molecular response milestones.

Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) bind Cys481 to disrupt B-cell receptor signaling in CLL and mantle cell lymphoma; second-generation agents reduce off-target TEC/EGFR toxicities (atrial fibrillation, bleeding, hypertension), while non-covalent pirtobrutinib overcomes acquired C481S resistance.

Clinical oncology pharmacists must educate patients that early post-initiation lymphocyte surges during BTK inhibitor therapy represent benign redistribution lymphocytosis (tissue homing inhibition) rather than disease progression, and enforce perioperative hold protocols (3–7 days) to prevent hemorrhagic complications.

JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) manage myelofibrosis splenomegaly and systemic symptoms; agent choice is guided by baseline cytopenias (pacritinib in severe thrombocytopenia <50k/mcL), transfusion-dependent anemia (momelotinib ACVR1 inhibition), and Wernicke encephalopathy surveillance (fedratinib thiamine monitoring).

Targeted AML kinase inhibitors require vigilant toxicity interception, including recognition and immediate corticosteroid management (dexamethasone 10 mg IV Q12H) of IDH-differentiation syndrome and mandatory cardiac QTc surveillance during FLT3 inhibitor therapy (midostaurin, gilteritinib, quizartinib).

Last updated: August 2026

6.2 Hematologic Small-Molecule Kinase Inhibitors

Targeted small-molecule kinase inhibitors have transformed hematologic malignancies from fatal conditions requiring intensive cytotoxic chemotherapy or allogeneic stem cell transplantation into manageable chronic diseases. The archetype of targeted therapeutics— BCR-ABL1 Tyrosine Kinase Inhibitors —demonstrated that inhibiting a single driver oncoprotein can induce deep molecular remissions and normalize life expectancy in Chronic Myeloid Leukemia (CML).

Modern hematologic oncology relies on an expanding armamentarium of kinase inhibitors targeting BCR-ABL1 , Bruton Tyrosine Kinase (BTK) , Janus Kinases (JAK1/2) , Fms-like Tyrosine Kinase 3 (FLT3) , and Isocitrate Dehydrogenase (IDH1/2) . Clinical oncology pharmacists play an essential role in navigating complex resistance mutations, interpreting quantitative molecular responses, preventing life-threatening toxicities, and optimizing pharmacotherapy.

1. BCR-ABL1 Inhibitors in CML and Philadelphia Chromosome-Positive (Ph+) ALL

The reciprocal chromosomal translocation t(9;22)(q34;q11.2) creates the Philadelphia chromosome (Ph) , fusing the BCR gene on chromosome 22 with the ABL1 non-receptor tyrosine kinase gene on chromosome 9. The resulting chimeric BCR-ABL1 fusion protein possesses constitutive, deregulated tyrosine kinase activity that drives uncontrolled granulocytic proliferation, cytokine independence, and resistance to apoptosis. +-----------------------------------------------------------------------------+

  • | BCR-ABL1 KINASE DOMAIN & INHIBITOR BINDING SITES |
  • | |
  • | [ATP-BINDING POCKET] <---------------------------------------------+ |
  • | - Target of competitive catalytic inhibitors: | |
  • | * 1st Gen: Imatinib | |
  • | * 2nd Gen: Dasatinib, Nilotinib, Bosutinib | |
  • | * 3rd Gen: Ponatinib (Engineered with carbon-carbon triple bond | |
  • | ethynyl linker to bypass bulky isoleucine in T315I) | |
  • | | |
  • | [GATEKEEPER RESIDUE: Threonine-315 (T315)] | |
  • | - Mutation: T315I (Threonine to Isoleucine substitution) | |
  • | - Eliminates hydrogen bond and creates steric clash for 1st/2nd-gen| |
  • | |
  • | [MYRISTOYL POCKET (ALLOSTERIC SITE)] <-----------------------------+ |
  • | - Target of STAMP Inhibitor: Asciminib |
  • | - Binds allosteric myristoyl binding site at C-terminal lobe |
  • | - Restores auto-inhibition of BCR-ABL1 kinase domain |
  • | - Retains high potency against ATP-pocket mutations including T315I |
  • +-----------------------------------------------------------------------------+
  • Generational Profiling of BCR-ABL1 Inhibitors

Generation / Agent Standard Dosing & Administration Food Effect & Bioavailability Signature Toxicities & Boxed Warnings Resistance Profile & Clinical Selection

Imatinib (1st Gen) 400 mg PO daily (up to 600–800 mg daily for blast phase/Ph+ ALL) Take with a meal and a large glass of water to minimize severe GI irritation. Periorbital/peripheral edema, fluid retention, muscle cramps, superficial edema, nausea, rash, myelosuppression. Baseline standard. Vulnerable to most kinase domain mutations (T315I, F317L, Y253H, E255K).

Dasatinib (2nd Gen) 100 mg PO daily (140 mg daily for accelerated/blast phase) With or without food. Pleural & pericardial effusions (15–30%; manage with dose hold, diuretics, short-course steroids), Pulmonary Arterial Hypertension (PAH) , platelet dysfunction/bleeding. Severe PPI/H2RA interaction (pH-dependent). Active against most imatinib-resistant mutations EXCEPT T315I and F317L/V/I/C.

Nilotinib (2nd Gen) 300 mg PO BID (frontline) or 400 mg PO BID (second-line) STRICT EMPTY STOMACH (1 hr before or 2 hr after food). Food increases bioavailability by 82%, causing dangerous cardiotoxicity. Black Box Warning for QTc Prolongation & Sudden Death. Progressive Arterial Occlusive Events (PAOD, stroke, MI in 10-15%), pancreatitis, hyperglycemia, hyperbilirubinemia. Active against most mutations EXCEPT T315I, Y253H, E255K/V, F359V/C. Avoid in patients with peripheral vascular disease or diabetes.

Bosutinib (2nd Gen) 400 mg PO daily (frontline) or 500 mg PO daily (second-line) Take with food . Early severe diarrhea (70–80%, Grade 3 in 10%) , nausea, transaminitis. Lowest rate of vascular occlusive events among 2nd-gen TKIs. Active against most mutations EXCEPT T315I and V299L. Excellent choice for patients with pre-existing cardiovascular/arterial disease.

Ponatinib (3rd Gen) Start at 45 mg PO daily ; reduce to 15 mg daily once BCR-ABL1 <= 1% is achieved With or without food. Black Box Warnings for Fatal Arterial Occlusions (25-35%), Venous Thromboembolism, Heart Failure, Hepatotoxicity, Pancreatitis. Dose-dependent vascular toxicity. Potent activity against T315I gatekeeper mutation. Essential option for T315I or failure of multiple prior TKIs. OPTIC trial established response-based dose de-escalation.

Asciminib (STAMP) 400 mg PO daily or 40 mg PO BID (200 mg PO BID for T315I mutation) Take on an empty stomach (at least 2 hr before or 1 hr after food). Well tolerated: Mild fatigue, arthralgias, mild myelosuppression, asymptomatic lipase elevation, hypertension. Significantly lower cardiovascular toxicity than ponatinib. Specifically Targets the ABL Myristoyl Pocket (STAMP). Overcomes ATP-binding site mutations. FDA-approved for Ph+ CML-CP after >=2 prior TKIs and for T315I mutation (at 200 mg BID).

European LeukemiaNet (ELN) Molecular Milestones in CML

Molecular response is monitored by quantitative RT-PCR on the International Scale (IS):

Early Molecular Response (3 Months): B C R − A B L 1 I S ≤ 10 % BCR-ABL1^{IS} \le 10\% BCR − A B L 1 I S ≤ 10% (indicates high likelihood of achieving optimal long-term survival).

Major Molecular Response (MMR / MR3.0 at 12 Months): B C R − A B L 1 I S ≤ 0.1 % BCR-ABL1^{IS} \le 0.1\% BCR − A B L 1 I S ≤ 0.1% (3-log reduction from standardized baseline; prevents disease progression to accelerated/blast phase).

Deep Molecular Response (MR4.0 ≤ 0.01 % \le 0.01\% ≤ 0.01% and MR4.5 ≤ 0.0032 % \le 0.0032\% ≤ 0.0032% ): Prerequisite for attempting Treatment-Free Remission (TFR) in stable patients after >=3–5 years of TKI therapy with >=2 years of sustained MR4.0/4.5.

2. Bruton Tyrosine Kinase (BTK) Inhibitors

Bruton Tyrosine Kinase (BTK) is an essential non-receptor cytoplasmic kinase within the B-cell receptor (BCR) signaling cascade. B-cell receptor cross-linking triggers BTK activation, activating downstream PLC-gamma-2, NF-kappa-B, and MAPK pathways that mediate B-cell proliferation, survival, and tissue adhesion in Chronic Lymphocytic Leukemia (CLL / SLL) , Mantle Cell Lymphoma (MCL) , and Waldenström Macroglobulinemia (WM) . +-----------------------------------------------------------------------------+

  • | BTK INHIBITOR GENERATION & SELECTIVITY |
  • | |
  • | 1ST GENERATION: Ibrutinib (RESONATE / RESONATE-2) |
  • | - Irreversible covalent inhibitor binding to Cysteine-481 (Cys481) |
  • | - Broad off-target kinase inhibition: TEC, EGFR, ITK, SRC, ERBB2 |
  • | - High incidence of: Atrial Fibrillation (12-16%), Hypertension (30-40%), |
  • | Major Bleeding (3-5%), Diarrhea, Arthralgias, Skin/Nail fragility |
  • | | |
  • | v |
  • | 2ND GENERATION (SELECTIVE): Acalabrutinib, Zanubrutinib |
  • | - Highly selective irreversible Cys481 inhibitors; spare TEC, EGFR, ITK |
  • | - ELEVATE-RR Trial (Acalabrutinib vs Ibrutinib in R/R CLL): |
  • | Non-inferior PFS with significantly lower Atrial Fibrillation (9% vs 16%)|
  • | - ALPINE Trial (Zanubrutinib vs Ibrutinib in R/R CLL): |
  • | Superior PFS (HR 0.65) and lower cardiac toxicity (AFib 5% vs 12%) |
  • | | |
  • | v |
  • | NON-COVALENT (REVERSIBLE): Pirtobrutinib (BRUIN Trial) |
  • | - Non-covalent, reversible binding that does NOT require the Cys481 residue|
  • | - Overcomes acquired BTK C481S resistance mutations |
  • | - Highly efficacious in CLL and MCL previously failing covalent BTKi & BCL2i|
  • +-----------------------------------------------------------------------------+
  • Master BTK Inhibitor Pharmacotherapy Comparison

Parameter Ibrutinib Acalabrutinib Zanubrutinib Pirtobrutinib

Binding Mechanism Irreversible covalent (Cys481) Irreversible covalent (Cys481) Irreversible covalent (Cys481) Non-covalent reversible

Kinase Selectivity Low (off-target TEC, EGFR, ITK) High High Highly selective

Standard Dosing 420 mg PO daily (CLL/WM); 560 mg PO daily (MCL) 100 mg PO BID 160 mg PO BID or 320 mg PO daily 200 mg PO daily

Acid-Suppression Dependency None Capsule: Avoid PPIs; separate H2RAs by 2h and antacids by 2h.; (Tablet formulation is pH-independent) None None

  • Atrial Fibrillation Risk 12–16% 4–9% 3–5% 1–3%
  • Bleeding / Platelet Inhibition 3–5% major bleeding; 50% minor bruising Lower Lower Low

Unique Adverse Effects Diarrhea, rash, nail cracking Early transient headache (20-30%) (caffeine/APAP responsive, resolves in 2–4 wks) Neutropenia (higher than ibrutinib, but lower infection rate) Fatigue, contusion, diarrhea

Clinical Practice Pearls for BTK Inhibitors

Redistribution Lymphocytosis: Within the first 2–4 weeks of initiating any BTK inhibitor, patients experience a marked increase in absolute lymphocyte count (ALC), often doubling or tripling baseline WBC. Mechanism: BTK inhibition blocks chemokine-mediated (CXCL12/CXCL13) and integrin-mediated tissue adhesion, forcing malignant B cells out of lymph nodes, spleen, and bone marrow into peripheral blood. This is accompanied by rapid reduction in lymphadenopathy and splenomegaly. It does not represent progressive disease; pharmacists must reassure patients and avoid premature discontinuation.

Perioperative Anticoagulation & Surgical Hold Guidelines: BTK inhibitors irreversibly inhibit collagen-induced platelet aggregation via off-target TEC and BTK inhibition. Hold Protocol: Withhold BTK inhibitors for 3 to 7 days before and after minor or major surgical procedures depending on bleeding risk. Avoid concomitant warfarin due to excessive risk of intracranial hemorrhage; when anticoagulation is mandatory (e.g., for atrial fibrillation), direct oral anticoagulants (DOACs: apixaban, rivaroxaban) are preferred with rigorous clinical surveillance.

3. Janus Kinase (JAK) Inhibitors in Myeloproliferative Neoplasms (MPNs)

The Janus Kinase / Signal Transducer and Activator of Transcription (JAK-STAT) pathway transduces signals from hematopoietic growth factor and cytokine receptors (erythropoietin, thrombopoietin, G-CSF, IL-6). The somatic JAK2 V617F gain-of-function mutation (present in >95% of Polycythemia Vera and 50–60% of Primary Myelofibrosis and Essential Thrombocythemia) drives constitutive intracellular phosphorylation, excessive myeloproliferation, and severe systemic inflammation. +-----------------------------------------------------------------------------+

  • | JAK INHIBITOR COMPARATIVE SPECTRUM & CLINICAL NICHES |
  • | |
  • | 1. RUXOLITINIB (COMFORT-I & COMFORT-II Trials) |
  • | - Targets: JAK1 and JAK2 |
  • | - Indications: Myelofibrosis (Intermediate-2/High risk), PV, GVHD |
  • | - Major Benefits: Splenomegaly reduction (>=35% spleen volume), |
  • | profound suppression of constitutional B-symptoms, improved survival |
  • | - Toxicities: Dose-dependent Anemia & Thrombocytopenia; Herpes Zoster, |
  • | non-melanoma skin cancer; WITHDRAWAL REBOUND (requires slow taper) |
  • | |
  • | 2. FEDRATINIB (JAKARTA Trial) |
  • | - Targets: JAK2 and FLT3 (spares JAK1) |
  • | - Indications: Primary or secondary Myelofibrosis (frontline or post-rux)|
  • | - Signature Warning: Black Box Warning for WERNICKE ENCEPHALOPATHY |
  • | (Mandatory baseline and periodic Thiamine [Vitamin B1] monitoring) |
  • | |
  • | 3. PACRITINIB (PERSIST-1 & PERSIST-2 Trials) |
  • | - Targets: JAK2, IRAK1, CSF1R (spares JAK1) |
  • | - Specialized Niche: Approved for Myelofibrosis with SEVERE |
  • | THROMBOCYTOPENIA (Platelet count < 50,000/mcL); no dose reduction req|
  • | - Toxicities: GI diarrhea/nausea, QTc prolongation |
  • | |
  • | 4. MOMELOTINIB (MOMENTUM Trial) |
  • | - Targets: JAK1, JAK2, and ACTIVIN A RECEPTOR TYPE 1 (ACVR1 / ALK2) |
  • | - Specialized Niche: Myelofibrosis with ANEMIA; ACVR1 inhibition down- |
  • | regulates liver HEPCIDIN, restoring iron availability and inducing |
  • | transfusion independence in anemic myelofibrosis patients |
  • +-----------------------------------------------------------------------------+

Warning

Ruxolitinib Withdrawal Syndrome: Abrupt discontinuation of ruxolitinib triggers a sudden surge in inflammatory cytokines ("cytokine rebound"), manifesting as rapid return of massive splenomegaly, high fevers, hemodynamic instability, and septic-shock-like collapse. Ruxolitinib must never be abruptly stopped ; doses should be gradually tapered over several weeks under close clinical observation unless immediate cessation is mandated by life-threatening toxicity.

  • 4. FLT3 and IDH Inhibitors in Acute Myeloid Leukemia (AML)
  • FLT3 Inhibitors

Fms-like Tyrosine Kinase 3 ( FLT3 ) mutations occur in approximately 30% of newly diagnosed AML cases, divided into Internal Tandem Duplications (FLT3-ITD) (~25%, associated with high leukemic burden, early relapse, and poor prognosis) and Tyrosine Kinase Domain (FLT3-TKD) point mutations (~5%, predominantly D835).

Midostaurin (RATIFY Trial): First-generation multi-targeted kinase inhibitor approved for newly diagnosed FLT3 -mutated AML in combination with standard "7+3" induction (cytarabine + daunorubicin) and consolidation, followed by single-agent maintenance. RATIFY demonstrated a significant OS benefit (HR 0.78, p = 0.009) . Dosing: 50 mg PO BID given on Days 8–21 of each chemotherapy cycle.

Gilteritinib (ADMIRAL Trial): Second-generation highly selective FLT3 inhibitor active against both FLT3 -ITD and FLT3 -TKD (D835) mutations. In relapsed/refractory FLT3 -mutated AML, gilteritinib monotherapy (120 mg PO daily) demonstrated superior median OS (9.3 vs. 5.6 months; HR 0.64) compared to salvage cytotoxic chemotherapy. Toxicities: Differentiation Syndrome , elevated transaminases, elevated CPK, pancreatitis, and QTc prolongation.

Quizartinib (QuANTUM-First): Potent, selective second-generation FLT3 -ITD inhibitor approved for frontline FLT3 -ITD+ AML with 7+3. Carries a Boxed Warning / REMS program for severe QTc prolongation and ventricular arrhythmias .

IDH1 and IDH2 Inhibitors

Neomorphic mutations in Isocitrate Dehydrogenase 1 ( IDH1 R132) and 2 ( IDH2 R140/R172) produce the oncometabolite 2-hydroxyglutarate (2-HG) , which blocks hematopoietic differentiation.

Ivosidenib (IDH1 Inhibitor): 500 mg PO daily. Approved for newly diagnosed or relapsed IDH1 -mutated AML (in combo with azacitidine or monotherapy) and IDH1 -mutated cholangiocarcinoma. Boxed warning for Differentiation Syndrome and QTc prolongation.

Enasidenib (IDH2 Inhibitor): 100 mg PO daily. Approved for relapsed/refractory IDH2 -mutated AML. Boxed warning for Differentiation Syndrome ; also causes indirect hyperbilirubinemia via UGT1A1 inhibition.

Olutasidenib (IDH1 Inhibitor): 150 mg PO BID. Approved for relapsed/refractory IDH1 -mutated AML. +-----------------------------------------------------------------------------+

  • | IDH / FLT3 DIFFERENTIATION SYNDROME MANAGEMENT |
  • | |
  • | [PATHOPHYSIOLOGY] |
  • | Targeted inhibition releases the maturation arrest of leukemic blasts, |
  • | causing massive, synchronous differentiation into mature myeloid cells. |
  • | Massive cytokine release & tissue infiltration occur. |
  • | |
  • | [CLINICAL PRESENTATION] |
  • | - Unexplained fever, dyspnea, hypoxia, pulmonary infiltrates |
  • | - Pleural or pericardial effusions, peripheral edema, rapid weight gain |
  • | - Acute kidney injury, leukocytosis, hypotension |
  • | |
  • | [PHARMACIST-LED MANAGEMENT PROTOCOL] |
  • | 1. At earliest clinical suspicion, IMMEDIATELY INITIATE: |
  • | * DEXAMETHASONE 10 mg IV every 12 hours (continue for >=3 days after |
  • | symptom resolution, then taper). |
  • | 2. If concurrent leukocytosis (WBC > 25,000-30,000/mcL), initiate |
  • | HYDROXYUREA 2 to 4 grams daily. |
  • | 3. DO NOT routinely hold the IDH/FLT3 inhibitor for mild-moderate DS; |
  • | HOLD therapy ONLY if severe pulmonary distress (mechanical ventilation)|
  • | or refractory hemodynamic instability persists despite steroids. |
  • +-----------------------------------------------------------------------------+